Stats Collaborative   Report issue

For profit Phase 3
Founded: Washington DC United States (1990)

Organization Overview

First Clinical Trial
2018
NCT03395392
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Stats Collaborative

Active Ingredients

Drugs in Phase 3 Trials (3)

cycloserine (seromycin) (2 trials)

ketamine (ketalar) (1 trial)

lurasidone (latuda) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bipolar Disorder (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Suicidal Ideation (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3